Advertisement

Cancer Immunology, Immunotherapy

, Volume 30, Issue 5, pp 262–268 | Cite as

In vitro differentiation and antigenic changes in human melanoma cell lines

  • Ludovico Guarini
  • Massimo Temponi
  • Gretchen M. Edwalds
  • Joseph R. Vita
  • Paul B. Fisher
  • Soldano Ferrone
Original articles

Summary

Malignant transformation of melanocytes may be associated with changes in the expression of HLA antigens and melanoma-associated antigens (MAA). To determine whether these changes reflect the differential expression of HLA antigens and MAA by melanocytes at different stages of differentiation, we have studied the effect of the reversible induction of differentiation by fibroblast interferon (interferon β) and/or 12-O-tetradecanoyl-phorbol 13-acetate (TPA) on the expression of HLA antigens and MAA by the melanoma cell lines DU-2, FO-1 and HO-1. The three melanoma cell lines differed in their sensitivity to the differentiating and antiproliferative activity of these two compounds and displayed an increased growth suppression and induction of differentiation, when incubated with the combination of TPA and interferon β. Incubation of the three melanoma cell lines with interferon β, TPA or their combination resulted in a differential modulation of the expression of membrane-bound high-molecular-mass melanoma-associated antigen, 115-kDa MAA, 100-kDa MAA, intercellular adhesion molecule 1, HLA class I antigens and gene products of the HLA-D region. Each melanoma cell line displayed a unique pattern of antigenic modulation when exposed to the two differentiating agents alone or in combination. No direct relationship was found between the effects of interferon β and/or TPA on the growth and differentiation of the three melanoma cell lines and the expression of HLA antigens or the MAA evaluated in the present study. These findings argue against a direct role of any of the antigens tested in the reversible induction of human melanoma cell differentiation in the in vitro system.

Keywords

Interferon Melanoma Cell Intercellular Adhesion Melanoma Cell Line Intercellular Adhesion Molecule 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ahmed MA, Guarini L, Ferrone S, Fisher PB (1988) Induction of differentiation in human melanoma cells by the combination of different classes of interferons or interferon plus mezerein. In: Viral oncogenes and cell differentiation. NY Acad Sci (in press)Google Scholar
  2. 2.
    Barnstable CJ, Bodmer WF, Brown G, Galpe G, Milstein C, Williams AF, Ziegler A (1978) Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens — new tools for genetic analysis. Cell 14: 9PubMedGoogle Scholar
  3. 3.
    Ferrone S, Imberti L, Natali PG, Schrier PI, Ruiter D (1986) HLA antigens on tumor cells. In: Monoclonal antibodies in cancer: advances in diagnosis and treatment. Futura Publishing Co., New York, p 111Google Scholar
  4. 4.
    Fisher PB (1984) Enhancement of viral transformation and expression of the transformed phenotype by tumor promoters. In: Tumor promotion and cocarcinogenesis in vitro: mechanisms of tumor promotion. CRC Press, Boca Raton, p 57Google Scholar
  5. 5.
    Fisher PB, Grant S (1985) Effects of interferon on differentiation of normal and tumor cells. Pharmacol Ther 27: 143PubMedGoogle Scholar
  6. 6.
    Fisher PB, Mufson RA, Weinstein IB (1981) Interferon inhibits melanogenesis in B-16 mouse melanoma cells. Biochem Biophys Res Commun 100: 823PubMedGoogle Scholar
  7. 7.
    Fisher PB, Schachter D, Abbott RE, Callaham MF, Huberman E (1984) Membrane lipid dynamics in human promyelocytic leukemia cells sensitive and resistant to 12-O-tetradecanoyl-phorbol-13-acetate induction of differentiation. Cancer Res 44: 5550PubMedGoogle Scholar
  8. 8.
    Fisher PB, Hermo H Jr, Pestka S, Weinstein IB (1985) Modulation of differentiation in murine and human melanoma cells by interferon and phorbol ester tumor promoters. In: Biological, Molecular and Clinical Aspects of Pigmentation. Univ of Tokyo Press, Tokyo, Japan, p 325Google Scholar
  9. 9.
    Fisher PB, Prignoli DR, Hermo H Jr, Weinstein IB, Pestka S (1985) Effects of combined treatment with interferon and mezerein on melanogenesis and growth in human melanoma cells. J Interferon Res 5: 11PubMedGoogle Scholar
  10. 10.
    Fisher PB, Hermo H Jr, Solowey WE, Dietrich MC, Edwalds GM, Weinstein IB, Langer JA, Pestka S, Giacomini P, Kusama M, Ferrone S (1986) Effect of recombinant human fibroblast interferon and mezerein on growth differentiation, immune interferon binding and tumor associated antigen expression in human melanoma cells. Anticancer Res 6: 765PubMedGoogle Scholar
  11. 11.
    Fisher PB, Griener JW, Mufson RA, Schlom J (1988) Molecules for tumor diagnosis and therapy. In: Application of genetic engineering. Marcel Dekker, New York, NY (in press)Google Scholar
  12. 12.
    Fisher PB, Schachter D, Mufson RA, Huberman E (1988) The role of membrane lipid dynamics and translocation of protein kinase C in the induction of differentiation in human promyelocytic leukemia cells. In: Pharmacological effects of lipids (in press)Google Scholar
  13. 13.
    Giacomini P, Aguzzi A, Pestka S, Fisher PB, Ferrone S (1984) Modulation by recombinant DNA leukocyte (α) and fibroblast (β) interferons of the expression and shedding of HLA-and tumor associated antigens by human melanoma cells. J Immunol 133: 1649PubMedGoogle Scholar
  14. 14.
    Giacomini P, Veglia F, Cordiali Fei P, Rehle T, Natali PG, Ferrone S (1984) Level of a membrane-bound high-molecularweight melanoma-associated antigen and of a cytoplasmic melanoma-associated antigen in surgically removed tissues and in sera from patients with melanoma. Cancer Res 44: 1281PubMedGoogle Scholar
  15. 15.
    Giacomini P, Gambieri R, Barbieri R, Nistico P, Tecce R, Pestka S, Gustafsson K, Natali PG, Fisher PB (1986) Regulation of the antigenic phenotype of human melanoma cells by recombinant interferon. Anticancer Res 6: 877PubMedGoogle Scholar
  16. 16.
    Greiner JW, Guadagni F, Noguchi P, Pestka S, Colcher D, Fisher PB, Schlom J (1987) Recombinant interferon enchances monoclonal antibody-targeting of carcinoma lesions in vivo. Science 235: 895PubMedGoogle Scholar
  17. 17.
    Greiner JW, Schlom J, Pestka S, Langer JA, Giacomini P, Kusama M, Ferrone S, Fisher PB (1987) Modulation of tumor associated antigen expression and shedding by recombinant human leukocyte and fibroblast interferons. Pharmacol Ther 31: 209Google Scholar
  18. 18.
    Huberman E, Heckman C, Langenbach R (1979) Stimulation of differentiated functions in human melanoma cells by tumor-promoting agents and dimethylsulfoxide. Cancer Res 39: 2618PubMedGoogle Scholar
  19. 19.
    Imai K, Natali PG, Kay NE, Wilson BS, Ferrone S (1982) Tissue distribution and molecular profile of a differentiation antigen detected by a monoclonal antibody (345.134S) produced against human melanoma cells. Cancer Immunol Immunother 12: 159Google Scholar
  20. 20.
    Imai K, Wilson BS, Bigotti A, Natali PG, Ferrone SA (1982) 94,000-Dalton glycoprotein expressed by human melanoma and carcinoma cells. J Natl Cancer Inst 68: 761PubMedGoogle Scholar
  21. 21.
    Leon JA, Mesa-Tejada R, Gutierrez MC, Vita JR, Greiner JW, Schlom J, Fisher PB (1989) Increased surface expression and shedding of tumor associated antigens by human breast carcinoma cells treated with recombinant human interferons on phorbol ester tumor promoters. Cancer Res (in press)Google Scholar
  22. 22.
    Lloyd KO (1983) Human tumor antigens: detection and characterization with monoclonal antibodies. In: Basic and clinical tumor Immunology. Martinus Nijhoff, Boston, Mass, p 159Google Scholar
  23. 23.
    Loms Ziegler-Heitbrock HW, Munker R, Johnson J, Petersmann I, Schmoeckel C, Riethmuller G (1985) In vitro differentiation of human melanoma cells analyzed with monoclonal antibodies. Cancer Res 45: 1344PubMedGoogle Scholar
  24. 24.
    Matsui M, Temponi M, Ferrone S (1987) Characterization of a monoclonal antibody-defined human melanoma-associated antigen susceptible to induction by immune interferon. J Immunol 139: 2088PubMedGoogle Scholar
  25. 25.
    Moschera JA, Woehle, D, Tsai KP, Chen CH, Tarnowski SJ (1986) Purification of recombinant human fibroblast interferon produced inEscherichia coli. Methods Enzymol 119: 177PubMedGoogle Scholar
  26. 26.
    Natali PG, Wilson BS, Imai K, Bigotti A, Ferrone S (1982) Tissue distribution, molecular profile and shedding of a cytoplasmic antigen identified by the monoclonal antibody 465.12S to human melanoma cells. Cancer Res 42: 583PubMedGoogle Scholar
  27. 27.
    Natali PG, Aguzzi A, Veglia F, Imai K, Burlage RS, Giacomini P, Ferrone S (1983) The impact of monoclonal antibodies on the study of human malignant melanoma. J Cutaneous Pathol 10: 514Google Scholar
  28. 28.
    Natali PG, Cavaliere R, Bigotti A, Nicotra MR, Russo C, Ng AK, Giacomini P, Ferrone S (1983) Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions. J Immunol 130: 1462PubMedGoogle Scholar
  29. 29.
    Natali PG, Bigotti A, Cavaliere R, Nicotra MR, Ferrone S (1984) Phenotyping of lesions of melanocyte origin with monoclonal antibodies to melanoma-associated antigens and to HLA antigens. J Natl Cancer Inst 73: 13PubMedGoogle Scholar
  30. 30.
    Natali PG, Bigotti A, Cavaliere R, Liao S-K, Taniguchi M, Matsui M, Ferrone S (1985) Heterogeneous expression of melanoma-associated antigens and HLA antigens by primary and multiple metastatic lesions removed from patients with melanoma. Cancer Res 45: 2883PubMedGoogle Scholar
  31. 31.
    Natali PG, Bigotti A, Cavaliere D, Ruiter DJ, Ferrone S (1988) HLA class II antigens synthesized by melanoma cells. Cancer Rev 9: 34Google Scholar
  32. 32.
    Pellegrino MA, Ng AK, Russo C, Ferrone S (1982) Heterogeneous distribution of determinants defined by monoclonal antibodies on HLA-A and B antigens bearing molecules. Transplantation 34: 18PubMedGoogle Scholar
  33. 33.
    Quaranta V, Pellegrino MA, Ferrone S (1981) Serological and immunochemical characterization of the specificity of four monoclonal antibodies to distinct antigenic determinants expressed on subpopulations of human Ia-like antigens. J Immunol 126: 548PubMedGoogle Scholar
  34. 34.
    Real FX, Houghton AN, Albino AP, Cordon-Cardo C, Melamed MR, Oettgen HF, Old LJ (1985) Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues. Cancer Res 45: 4401PubMedGoogle Scholar
  35. 35.
    Watson AJ, DeMars R, Trowbridge IS, Bach FH (1983) Detection of a novel human class II HLA antigen. Nature 304: 358PubMedGoogle Scholar
  36. 36.
    Wilson BS, Imai K, Natali PG, Ferrone S (1981) Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies. Int J Cancer 28: 293PubMedGoogle Scholar
  37. 37.
    Ziai RM, Imberti L, Tongson A, Ferrone S (1985) Differential modulation by recombinant immune interferon of the expression and shedding of HLA antigens and melanoma associated antigens by a melanoma cell line resistant to the antiproliferative activity of immune interferon. Cancer Res 45: 5877PubMedGoogle Scholar
  38. 38.
    Ziai MR, Imberti L, Kobayashi M, Perussia B, Trinchieri G, Ferrone S (1986) Distinct functional domains on the recombinant human immune interferon molecule. Cancer Res 46: 6187PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • Ludovico Guarini
    • 1
  • Massimo Temponi
    • 3
  • Gretchen M. Edwalds
    • 2
  • Joseph R. Vita
    • 2
  • Paul B. Fisher
    • 2
  • Soldano Ferrone
    • 3
  1. 1.Division of Pediatric Hematology/OncologyColumbia University, College of Physicians and SurgeonsNew YorkUSA
  2. 2.Departments of Neurological Surgery, Pathology and Urology, and Comprehensive Cancer Center/Institute of Cancer ResearchColumbia University, College of Physicians and SurgeonsNew YorkUSA
  3. 3.Department of Microbiology and ImmunologyNew York Medical CollegeValhallaUSA

Personalised recommendations